Aarkstore - Hyperlipidemia - Pipeline Review, H2 2014

Aarkstore Enterprise Aarkstore Enterprise

Description

‘Hyperlipidemia - Pipeline Review, H2 2014’, provides an overview of the Hyperlipidemia’s therapeutic pipeline.
For more details : http://goo.gl/UPSI67

Informations

• Publié par: Shubhangi
• Publié le: 07 mai 2015
• Nombre de lectures: 0
• Langue: English

Extrait

Aarkstore Enterprise


Aarkstore - Hyperlipidemia - Pipeline Review, H2 2014
Browse Full Report
@
http://www.aarkstore.com/pharmaceuticals-healthcare/63089/hyperlipidemia-pipelinereview
Published: Oct 2014 | 163 Pages
PDF : $ 2000 | Site Licence: $ 4000 | Enterprise Wide Licence : $ 6000
Summary
‘Hyperlipidemia - Pipeline Review, H2 2014’, provides an overview of the Hyperlipidemia’s
therapeutic pipeline.
This Market Research Report provides comprehensive information on the therapeutic
development for Hyperlipidemia, complete with comparative analysis at various stages, therapeutics
assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases. It also reviews key players
involved in the therapeutic development for Hyperlipidemia and special features on late-stage and
discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20
therapy areas and nearly 3,000 indications. The report is built using data and information sourced
from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings,
investor presentations and featured press releases from company/university sites and
industryspecific third party sources, put together by Global Markets Direct’s team. Drug profiles/records
featured in the report undergoes periodic updation following a stringent set of processes that ensures
that all the profiles are updated with the latest set of information. Additionally, including
live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to

Aarkstore Enterprise

gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and
relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hyperlipidemia
- The reviews key pipeline products under drug profile section which includes, product
description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hyperlipidemia and
enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hyperlipidemia products under development by companies and
universities/research institutes based on information derived from company and industry-specific
sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till
discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hyperlipidemia pipeline on the basis of target, MoA, route of administration and
molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate
effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective
counterstrategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for
Hyperlipidemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth
and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with
the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors

Aarkstore Enterprise

that drove them from pipeline

Order full Report with TOC and Sample page
visit:
http://www.aarkstore.com/pharmaceuticals-healthcare/63089/hyperlipidemia-pipelinereview
Table of Contents:
Introduction 7
Global Markets Direct Report Coverage 7
Hyperlipidemia Overview 8
Therapeutics Development 9
Pipeline Products for Hyperlipidemia - Overview 9 for - Comparative Analysis 10
Hyperlipidemia - Therapeutics under Development by Companies 11 - Investigation by Universities/Institutes 14 - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage 16
Hyperlipidemia - Products under Development by Companies 17 - Investigation by Universities/Institutes 20 - Companies Involved in Therapeutics Development 21
ACROVIS biostructures GmbH 21
Advinus Therapeutics Ltd. 22
Angion Biomedica Corp. 23
BiOrion Technologies B.V. 24
Celgene Corporation 25
Digna Biotech, S.L. 26
FibroGen, Inc. 27
Galectin Therapeutics, Inc. 28
Genfit SA 29
GenKyoTex S.A. 30
Gilead Sciences, Inc. 31
GNI Group Ltd. 32
La Jolla Pharmaceutical Company 33
LG Life Sciences, Ltd. 34
Nitto Denko Corporation 35
Pfizer Inc. 36

Aarkstore Enterprise

List Of Tables
Number of Products under Development for Hyperlipidemia, H2 2014 12 of for Hyperlipidemia - Comparative Analysis, H2 2014 13
Number of Products under by Companies, H2 2014 15 of Development by H2 2014 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18 by Early Stage H2 2014 19
Products under Development by Companies, H2 2014 20 by H2 2014 (Contd..1) 21
Products under by Companies, H2 2014 (Contd..2) 22

List Of Figures
Number of Products under Development for Hyperlipidemia, H2 2014 12 of for Hyperlipidemia - Comparative Analysis, H2 2014 13
Number of Products under by Companies, H2 2014 14 of Investigation by Universities/Institutes, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18 by Early Stage Products, H2 2014 19
Assessment by Monotherapy Products, H2 2014 48
Number of Products by Top 10 Targets, H2 2014 49 of by Stage and Top 10 Targets, H2 2014 50
Number of Products by Top 10 Mechanism of Actions, H2 2014 51
Related Market Research reports:
 Corticosteroid-Responsive Dermatoses - Pipeline Review, H1 2014
 Hematological Tumor - Pipeline Review, H1 2014
 Inflammation - Pipeline Review, H1 2014
 Opioid Induced Side Effects - Pipeline Review, H1 2014
 Skin Infections - Pipeline Review, H1 2014
 Restenosis - Pipeline Review, H1 2014
 Tauopathies - H1 2014
 Nasopharyngitis (Common Cold) - Pipeline Review, H1 2014
 Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Pipeline Review, H1 2014
 Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2014

Aarkstore Enterprise

About Aarkstore
Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We
specialize in providing online market business information on market research reports, books, magazines,
conference at competitive prices, and strive to provide excellent and innovative service to our customers
Contact Details:
Aarkstore Enterprise
Phone: [phone]
Email: [e-mail]
Our Website: http://www.aarkstore.com
Our Blog : http://www.aarkstore.com/blog/
Latest News : http://www.aarkstore.com/news
Facebook: https://www.facebook.com/aarkstoredotcom